

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

ANNOUNCEMENT

(1) INSIDE INFORMATION;
(2) PROPOSED CHANGE OF DIRECTORS; AND
(3) RE-DESIGNATION OF A DIRECTOR AND CHANGE OF CHAIRMAN
AND VICE CHAIRMAN

(1) INSIDE INFORMATION

References were made to the announcements of Biosino Bio-Technology and Science Incorporation (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 13 December 2024 and 30 December 2024 (the “**Announcements**”). Unless otherwise stated, capitalised terms used herein shall bear the same meanings as those defined in the Announcements.

Mr. Chen Peng, the President and an executive Director, has fully cooperated with the investigation, and the detention measures have been lifted. He has resumed his duties and responsibilities within the Group. According to Mr. Chen, the prior detention measures did not have any material adverse effect on himself or the Group.

(2) PROPOSED CHANGE OF DIRECTORS

Proposed removal of Director

Pursuant to Article 93 of the articles of association of the Company (the “**Articles of Association**”), a director will be deemed to have failed to perform his duties, if he fails to attend board meetings in person twice consecutively and does not delegate other directors to attend on his behalf; the board of directors of the company shall make recommendations to shareholders' general meetings to replace such director.

Considering Mr. Wu Lebin (“**Mr. Wu**”), the former Chairman of the Board and an executive Director, was no longer contactable by the Company since the end of November 2024, and he has failed to attend the Board meetings in person twice consecutively, nor has he delegated other Directors to attend the Board meetings on his behalf, the Board is of the view that Mr. Wu has failed to perform his duties as a Director. Up to the date of this announcement, the Board was still unable to directly contact or reach Mr. Wu. As such, the Board has recommended to remove Mr. Wu as a Director (the “**Proposed Removal**”). Pursuant to the Articles of the Association, the Proposed Removal is subject to the approval by the Shareholders at the next extraordinary general meeting of the Company (the “**EGM**”). The Board considers the Proposed Removal is in the interests of the Company and its shareholders (the “**Shareholders**”) as a whole.

Based on the work arrangements and the changes to the Board as disclosed in the Announcements and this announcement, the Board is of the view that the Proposed Removal would not have any significant adverse effect on the operations of the Group. Save for the abovementioned, the Board is not aware of any disagreement between Mr. Wu and the Board, nor is the Board aware of any other matters relating to the Proposed Removal that needs to be brought to the attention of the Shareholders and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Resignation of Director

The Board hereby announces that Mr. Lu Qi (“**Mr. Lu**”) has tendered his resignation to the Company as an independent non-executive Director due to his wish to devote more time to his other commitments (the “**Resignation**”). The Resignation shall become effective upon (i) the conclusion of the EGM; and (ii) the approval of the appointment of Mr. Fan Xiaoliang as an independent non-executive Director by the Shareholders at the EGM.

Mr. Lu has confirmed that he has no disagreement with the Board and there is no other matter that needs to be brought to the attention of the Shareholders or the Stock Exchange relating to the Resignation. The Board is also not aware of any other matters relating to the Resignation that need to be brought to the attention of the Shareholders and the Stock Exchange.

Proposed appointment of Directors

The Board is pleased to announce that Dr. Shen Sheng (沈勝) (“**Dr. Shen**”) and Mr. Fan Xiaoliang (范曉亮) (“**Mr. Fan**”) have been nominated by the eighth session of the Board as candidates for election at the EGM as a non-executive Director and an independent non-executive Director, respectively, (the “**Proposed Appointments**”) of the current session of the Board. Pursuant to the Articles of Association, the Proposed Appointments are subject to the approval by the Shareholders at the EGM.

Ordinary resolutions will be proposed at the EGM for the Proposed Removal and the Proposed Appointments. A circular containing further details in relation to the Proposed Removal and the Proposed Appointments, including but not limited to the nominees’ biographies, will be despatched to the Shareholders in due course.

There will be changes in composition of the Board committees following the changes in directorships. The Company will confirm such changes in the poll results announcement of the EGM.

(3) RE-DESIGNATION OF A DIRECTOR AND CHANGE OF CHAIRMAN AND VICE CHAIRMAN

The Board also announces that:

- (i) Mr. Chen Zhengyong (“**Mr. Chen**”), an executive Director and a Vice Chairman of the Board, has been appointed as the Chairman of the Board in place of Mr. Wu with effect from 30 May 2025; and
- (ii) Mr. Li Zhonghua (“**Mr. Li**”), a non-executive Director, has been re-designated to an executive Director with effect from 30 May 2025, and he has also been appointed as a Vice Chairman of the Board on the same date.

The biographical details of Mr. Chen and Mr. Li are set out as follows:

Executive Directors

Mr. Chen Zhengyong (陳正永), aged 61, is the Chairman of the Board, an executive Director and the legal representative of the Company. From 1983 to 1993, he was employed at Chengdu Tenth Hospital* (成都市第十醫院) where he was responsible for diagnostic testing. Since 1994, he has been engaged in the business of precision medicine and in vitro diagnostic. He has served as the chairman of the board of a number of companies including Sichuan Zhongsheng Medical Instrument Co., Ltd.* (四川中生醫療器械有限責任公司) (“**Sichuan Zhongsheng**”) since 2012, Sichuan Century Tongchang Health Management Co., Ltd.* (四川世紀同昌健康管理有限責任公司) since 2015 and Chengdu Tongchang Medical Laboratory Co., Ltd.* (成都同昌醫學檢驗所有限公司) since 2017. Mr. Chen obtained his diploma from Chongqing Medical and Pharmaceutical College (重慶醫藥高等專科學校) in clinical laboratory (檢驗專業) in 1983. He studied Chinese language and literature (漢語言文學專業) at Sichuan Broadcast Television University* (四川省廣播電視大學) (currently known as Sichuan Open University (四川開放大學)) from 1985 to 1988, studied Business Administration at Southwestern University of Finance and Economics (西南財經大學) from 2014 to 2016 and studied Business Administration at Peking University (北京大學) from 2018 to 2020. Mr. Chen joined the Company in May 2023.

Mr. Chen’s term of service with the Company will end at the expiration of the term of the current session of the Board. Mr. Chen does not receive any remuneration from the Company. His future remuneration shall be determined by the Board and the remuneration committee of the Company (the “**Remuneration Committee**”) with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, Mr. Chen has not held any directorship in any public companies where the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years, nor has he held any other positions with the Company or other members of the Group or had other major appointments or professional qualifications.

As at the date of this announcement, Sichuan Zhongsheng holds 10,000,000 domestic shares of the Company. As Mr. Chen owns 77.94% of equity interests in Sichuan Zhongsheng, he is deemed to be interested in all the domestic shares of the Company owned by Sichuan Zhongsheng under the SFO. Save as disclosed above, he does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations (as defined in the GEM Listing Rules) which are required to be disclosed pursuant to Part XV of the SFO.

As at the date of this announcement, save as disclosed above, Mr. Chen does not have any relationship with the Directors, senior management, substantial or controlling shareholders (as defined in the GEM Listing Rules) of the Company.

Save as disclosed above, there are no other matters relating to the appointment of Mr. Chen that should be disclosed pursuant to Rule 17.50(2) of the GEM Listing Rules and there are no other matters that need to be brought to the attention of the Shareholders and the Stock Exchange.

Mr. Li Zhonghua (李忠華), aged 61, is the Vice Chairman of the Board and an executive Director. Mr. Li was a graduate student at Kunming Medical University (昆明醫科大學) (previously known as Kunming Medical College (昆明醫學院)) and obtained his EMBA degree from Peking University HSBC Business School. Mr. Li has experience working as a supervisor teach in medical diagnostic profession and a clinical laboratory doctor at the hospital. From 1993 to December 1997, Mr. Li worked at Shanghai Kehua Biotechnology Co., Ltd.* (上海科華生物科技股份有限公司工作). In 1998, Mr. Li commenced his own business and was a senior management personnel that inspects medical equipment products in Yunnan Province. Mr. Li founded Kunming Huasheng Technology Co., Ltd.* (昆明華聖科技有限公司) and Yunnan Guoke Kangyi Biotechnology Co., Ltd.* (雲南國科康儀生物科技股份有限公司). Mr. Li joined the Company in May 2023.

Mr. Li's term of service with the Company will end at the expiration of the term of the current session of the Board. Mr. Li does not receive any remuneration from the Company. His future remuneration shall be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, Mr. Li has not held any directorship in any public companies where the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years, nor has he held any other positions with the Company or other members of the Group or had other major appointments or professional qualifications.

As at the date of this announcement, Mr. Li does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations (as defined in the GEM Listing Rules) which are required to be disclosed pursuant to Part XV of the SFO.

As at the date of this announcement, other than being the father of Mr. Li Yangyixiong, a substantial Shareholder, Mr. Li did not have any relationship with the Directors, senior management, substantial or controlling shareholders (as defined in the GEM Listing Rules) of the Company.

Save as disclosed above, there are no other matters relating to the re-designation and appointment of Mr. Li that should be disclosed pursuant to Rule 17.50(2) of the GEM Listing Rules and there are no other matters that need to be brought to the attention of the Shareholders and the Stock Exchange.

* *For identification purpose only*

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Chen Zhengyong
Chairman and Executive Director

Beijing, the PRC, 30 May 2025

As at the date of this announcement, the Board comprises:

Chairman and executive Director

Mr. Chen Zhengyong (陳正永先生)

Vice chairman and executive Director

Mr. Li Zhonghua (李忠華先生)

President and executive Director

Mr. Chen Peng (陳鵬先生)

Executive Director

Mr. Wu Lebin (吳樂斌先生)

Vice chairman and non-executive Director

Mr. Yang Peng (楊鵬先生)

Non-executive Director

Dr. Gao Guangxia (高光俠博士)

Independent non-executive Directors

Prof. Shen Zuojun (沈佐君教授), Mr. Lu Qi (陸琪先生), Prof. Shen Jiangang (沈劍剛教授)
and Dr. He Xin (何欣博士)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkgem.com for at least 7 days from the date of its posting and on the website of the Company at www.zhongsheng.com.cn.